A Novel, Ruxolitinib‐Sensitive, CCDC6 :: JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera‐Like, Myeloproliferative Neoplasm

Documenti analoghi

• Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
  di: Tiziano Barbui, et al.
  Pubblicazione: (2025)
• Topics of Interest in Women With Myeloproliferative Neoplasms
  di: Natasha Szuber, et al.
  Pubblicazione: (2025)
• Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
  di: Paola Guglielmelli, et al.
  Pubblicazione: (2024)
• Designing JAK2 Inhibitors Beyond Myeloproliferative Neoplasms ‐ Theoretical and Experimental Analysis for Solid Cancers
  di: A. S. Achutha, et al.
  Pubblicazione: (2024)
• Concurrent Presentation of Pure Red Cell Aplasia and Myeloproliferative Neoplasm, Unclassifiable With JAK2 and MPL Mutations
  di: Qiuyang Li, et al.
  Pubblicazione: (2025)